Europe

Home page

Europe

J&J expects COVID vaccine sales to jump as much as 46% in 2022

25 January 2022 17:06 (UTC +04:00)

Johnson & Johnson said on Tuesday it expects to generate as much as $3.5 billion from the sale of its COVID-19 vaccine this year compared to $2.39 billion in 2021, in a sign of easing manufacturing problems and increasing demand, APA reports citing Reuters.

Delivery delays and an uneven demand during last year resulted in the drugmaker narrowly missing its goal of garnering $2.50 billion in vaccine sales in 2021.

J&J shares fell 1.2% before the opening bell as overall fourth-quarter sales also missed market expectations due to a bleak performance by a few of the big revenue drivers such as cancer drug Imbruvica and Crohn's disease treatment Stelara.

Contributions from the coronavirus vaccine are expected to be a small part of J&J's overall sales as the company sells it at a not-for-profit price.